Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Phase 2

Completed

• Conditions: Influenza
• Interventions: Biological: Allantoic Split Inactivated Seasonal flu Vaccine; Biological: VAXIGRIP

• Registration Number: NCT03016143
• Lead Sponsor: Research Institute for Biological Safety Problems

Brief Summary

The study is a single centre, phase II, double-blind, randomized, comparative trial that explored the immunogenicity and safety of single dose a allantoic split inactivated seasonal influenza vaccine and VAXIGRIP vacccine in healthy adults the two age groups (in persons 18 to 60 years of age and older than 60 years).

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10
• Primary Completion: 2016-11
• Study Completion: 2016-12
• Status Verified: 2017-01
• Study First Submitted: 2017-01-04
• Study First Submitted QC: 2017-01-08
• Study First Posted: 2017-01-10
• Last Update Submitted: 2018-06-06
• Last Update Posted: 2018-06-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• volunteers (men and women) aged 18 years and older.
• Literate and willing to provide written informed consent.
• A signed informed consent.

Exclusion Criteria

• Available in anamnaze volunteer at any allergic reactions.
• Allergic reactions to chicken proteins, or any preceding vaccination.
• Acute illness with a fever (37.0 C).
• Vaccination against influenza in the 2015/2016 season.
• Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.
• Hypersensitivity after previous administration of any vaccine.
• History of chronic alcohol abuse and/or illegal drug use.
• Any clinically significant abnormal laboratory finding.
• A positive pregnancy test for all women of childbearing potential.
• Administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment.
• Acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives.
• History of leukemia or any other blood or solid organ cancer.
• Receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study.
• Participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study.
• Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)	Allantoic Split Inactivated Seasonal flu Vaccine	100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
Group #4 (Vaccine VAXIGRIP)	VAXIGRIP	50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)	Allantoic Split Inactivated Seasonal flu Vaccine	100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
Group #3 (Vaccine VAXIGRIP)	VAXIGRIP	50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP

Primary Outcome Measures

Name	Time	Method
Geometric Mean Fold Increase in HI Antibody Titer	Change from Baseline HI Antibody Titer at 21 days	Geometric mean fold increase in HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination, as compared with Baseline.
Seroconversion Rate of Hemagglutination Inhibition (HI) Antibody Titer	Change from Baseline HI Antibody Titer at 21 days	Seroconversion rate was measured by hemagglutination inhibition (HI) antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from the Baseline HI antibody titer in participants with a Baseline titer ≥10, or achieving an HI antibody titer of ≥40 in participants with a Baseline titer \<10.
Seroprotection Rate of HI Antibody Titer	Change from Baseline HI Antibody Titer at 21 days	Seroprotection rate, defined as the percentage of participants with HI antibody titer of ≥40, was measured by HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination. Day 1 data is reported for reference.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)	21 Days	Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Serious adverse events (SAEs), including abnormal laboratory findings	21 Days	Serious adverse events (SAEs) are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Percentage of Participants With Abnormal Safety Laboratory Tests at Least Once Post Dose Reported as AEs	21 Days	The percentage of participants with any abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout the study reported as AEs.
Percentage of Participants With Solicited Local and Systemic Adverse Events (AEs)	21 Days	Participants recorded solicited injection site and systemic adverse events in a Subject Diary. Solicited Locals AEs were: Injection Site Pain, Injection Site Redness, Injection Site Swelling, Injection Site Induration and Injection Site Ecchymosis. Solicited Systemic AEs were: Pyrexia, Malaise, Chills, Fatigue, Headache, Sweaty, Myalgia, Arthralgia, Nausea and Vomiting.

Trial Locations

Locations (1)

Kazakh National Medical University; 🇰🇿 Almaty, Kazakhstan